Stock Financial Ratios, Dividends, Split History

HRS / Harris Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price152.15
Volume604,300.00
Market Cap ($M)18,004.05
Enterprise Value ($M)20,952.05
Book Value ($M)3,137.00
Book Value / Share26.42
Price / Book5.74
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 119,628,884
Weighted Average Number Diluted Shares Outstanding Adjustment 1,700,000
Weighted Average Number Of Diluted Shares Outstanding 124,300,000
Weighted Average Number Of Shares Outstanding Basic 122,600,000
Common Shares Outstanding 119,762,879
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.07
Return on Assets (ROA)0.05
Return on Equity (ROE)0.18
Balance Sheet (mrq) ($M)
Assets10,070.00
Liabilities6,933.00
Quick Ratio0.68
Current Ratio1.12
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue1,039,000,000.00
Sales Revenue Goods Net4,667,000,000.00
Sales Revenue Net5,900,000,000.00
Export Revenue1,300,000,000.00
Sales Revenue Services Net1,233,000,000.00
Disposal Group Including Discontinued Operations Advanced Paymentsand Unearned Revenue0.00
Net Income553.00
Earnings Per Share Basic4.50
Earnings Per Share Diluted4.44
Cash Flow Statement (mra) ($M)
Cash From Operations569.00
Cash from Investing870.00
Cash from Financing870.00
Identifiers and Descriptors
CUSIP413875105
Central Index Key (CIK)202058
Related CUSIPS
413875955 041387510

Split History

Stock splits are used by Harris Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Telecom Stock Roundup: ADTRAN's & Ericsson's Q2 Earnings & More

3h zacks
In the last five trading days, telecom stocks’ initial uptrend was replaced by a sharp fall, followed by a relatively flat trajectory and an eventual decline. The volatile trend was the likely result of the continuing trade war with China. The Trump administration has reportedly drawn up a list of goods for imposing tariffs on an additional $200 billion worth of products imported from China. Although the earlier lists mostly spared telecom products, the latest round of tariffs is likely to impact network routers and components that go into digital signal processing, TVs, monitors and telecom gear. (8-0)

The 20 Stocks From Goldman Sachs' Buy List That You Should Actually Consider | InvestorPlace

2018-07-11 investorplace
But recently, the equity research team at Goldman compiled a list of stocks within the company’s coverage universe that have the most potential upside to their price targets. The list is long (about 40 stocks), and Goldman pegs all of them as having roughly 30% or more upside to their price target. (28-1)

Harris Wins IDIQ Contracts to Enhance Geospatial Databases

2018-07-11 zacks
Harris Corporation (HRS - Free Report) recently secured three multi-award IDIQ contracts with ceilings totaling $1.5 billion to provide geospatial data services to the National Geospatial-Intelligence Agency (“NGA”) for a period of up to 10 years. (6-0)

Top Analyst Upgrades and Downgrades: Allergan, Cheniere, Clean Energy, Facebook, Fiat Chrysler, Intel, NetApp and More

2018-07-05 247wallst
Stocks were looking for a very strong open on Thursday after the Independence Day holiday had U.S. markets closed on Wednesday. The prior trend of buying the dips has been less reliable during most of 2018 than in prior years. Many investors have been considering how they want their investments positioned ahead of the midterm elections and also for the longer term. (57-0)

Telecom Stock Roundup: VZ Reality Ad Launch, CBB's Merger Deal & More

2018-06-21 zacks
In the last five trading days, telecom stocks flattered to deceive as the initial upturn was replaced by a persistent downturn for the most part of the past week as President Trump renewed fears of a fresh trade war with China. The on-again off-again trade war between the United States and China took a new turn when Trump imposed a fresh salvo of tariffs worth $50 billion on Chinese imports last week. (43-0)

CUSIP: 413875105